JPMorgan Chase & Co. Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

JPMorgan Chase & Co. increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 173.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 277,204 shares of the specialty pharmaceutical company's stock after purchasing an additional 175,892 shares during the period. JPMorgan Chase & Co. owned 0.86% of Collegium Pharmaceutical worth $10,711,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after purchasing an additional 792 shares during the period. CWM LLC raised its stake in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after purchasing an additional 736 shares during the period. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after purchasing an additional 483 shares during the period. Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical during the third quarter valued at about $72,000. Finally, AXA S.A. acquired a new stake in shares of Collegium Pharmaceutical during the second quarter valued at about $209,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on COLL shares. Piper Sandler reiterated a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a report on Friday. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Stock Up 2.7 %

Shares of NASDAQ:COLL traded up $0.88 during trading on Monday, hitting $33.79. 421,351 shares of the company were exchanged, compared to its average volume of 593,934. The stock has a market capitalization of $1.09 billion, a P/E ratio of 14.56 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29. The firm's 50 day moving average price is $30.56 and its 200-day moving average price is $34.08.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.